Since then, CD82 expression levels have been reported to be negatively correlated to the metastatic potential in prostate tumors [2–4] and other epithelial tumors including gastric [5], colon [6, 7], cervix [8, 9], breast [10, 11], skin [12], bladder [13, 14] lung [15], pancreas [16], liver [17–19], and thyroid [20]. Here, CD82 is linked to prostate neoplasm.